These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064 [TBL] [Abstract][Full Text] [Related]
10. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923 [TBL] [Abstract][Full Text] [Related]
11. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387 [TBL] [Abstract][Full Text] [Related]
12. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238 [TBL] [Abstract][Full Text] [Related]
13. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851 [TBL] [Abstract][Full Text] [Related]
14. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506 [TBL] [Abstract][Full Text] [Related]
15. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Johan MF; Bowen DT; Frew ME; Goodeve AC; Wilson GA; Peake IR; Reilly JT Br J Haematol; 2004 Mar; 124(6):843-4. PubMed ID: 15009076 [No Abstract] [Full Text] [Related]
16. FLT3 mutations are associated with other molecular lesions in AML. Carnicer MJ; Nomdedéu JF; Lasa A; Estivill C; Brunet S; Aventín A; Sierra J Leuk Res; 2004 Jan; 28(1):19-23. PubMed ID: 14630076 [TBL] [Abstract][Full Text] [Related]
17. Mutations of PTPN11 are rare in adult myeloid malignancies. Hugues L; Cavé H; Philippe N; Pereira S; Fenaux P; Preudhomme C Haematologica; 2005 Jun; 90(6):853-4. PubMed ID: 15951301 [TBL] [Abstract][Full Text] [Related]
18. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3. Smith ML; Arch R; Smith LL; Bainton N; Neat M; Taylor C; Bonnet D; Cavenagh JD; Andrew Lister T; Fitzgibbon J Br J Haematol; 2005 Feb; 128(3):318-23. PubMed ID: 15667533 [TBL] [Abstract][Full Text] [Related]
20. FLT3/ITD mutation signaling includes suppression of SHP-1. Chen P; Levis M; Brown P; Kim KT; Allebach J; Small D J Biol Chem; 2005 Feb; 280(7):5361-9. PubMed ID: 15574429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]